Comparative Pharmacology
Head-to-head clinical analysis: DESFLURANE versus DIPRIVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESFLURANE versus DIPRIVAN.
DESFLURANE vs DIPRIVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
None Documented
None Documented
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Clinical Note
moderateDesflurane + Torasemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide."
Clinical Note
moderateDesflurane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Desflurane is combined with Etacrynic acid."
Clinical Note
moderateDesflurane + Furosemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Furosemide."
Clinical Note
moderateDesflurane + Bumetanide
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Desflurane is combined with Bumetanide."